Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Leases (2016 - 2019)

Enanta Pharmaceuticals filings provide 5 years of Capital Leases readings, the most recent being $200000.0 for Q3 2019.

  • On a quarterly basis, Capital Leases fell 31.74% to $200000.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $200000.0, a 31.74% decrease, with the full-year FY2019 number at $200000.0, down 31.74% from a year prior.
  • Capital Leases hit $200000.0 in Q3 2019 for Enanta Pharmaceuticals, down from $224000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $529000.0 in Q3 2015 to a low of $175000.0 in Q2 2015.
  • Median Capital Leases over the past 5 years was $368500.0 (2017), compared with a mean of $364166.7.
  • Biggest five-year swings in Capital Leases: surged 173.14% in 2016 and later plummeted 31.74% in 2019.
  • Enanta Pharmaceuticals' Capital Leases stood at $513000.0 in 2015, then dropped by 14.23% to $440000.0 in 2016, then fell by 18.64% to $358000.0 in 2017, then fell by 24.3% to $271000.0 in 2018, then decreased by 26.2% to $200000.0 in 2019.
  • The last three reported values for Capital Leases were $200000.0 (Q3 2019), $224000.0 (Q2 2019), and $249000.0 (Q1 2019) per Business Quant data.